TransMedics Group, Inc. (NASDAQ:TMDX) Stake Boosted by OneDigital Investment Advisors LLC

OneDigital Investment Advisors LLC increased its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 52.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,989 shares of the company's stock after buying an additional 2,065 shares during the quarter. OneDigital Investment Advisors LLC's holdings in TransMedics Group were worth $403,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TMDX. NBC Securities Inc. acquired a new stake in TransMedics Group in the 1st quarter valued at about $25,000. Atlas Capital Advisors Inc. bought a new stake in shares of TransMedics Group during the 4th quarter worth $31,000. AlphaQuest LLC bought a new stake in shares of TransMedics Group during the 4th quarter worth $52,000. Rakuten Securities Inc. boosted its stake in shares of TransMedics Group by 68.3% during the 4th quarter. Rakuten Securities Inc. now owns 1,355 shares of the company's stock worth $84,000 after acquiring an additional 550 shares in the last quarter. Finally, Sava Infond d.o.o. bought a new stake in shares of TransMedics Group during the 4th quarter worth $94,000. 99.67% of the stock is owned by institutional investors.

TransMedics Group Price Performance

TMDX stock opened at $124.78 on Friday. The firm has a market cap of $4.22 billion, a price-to-earnings ratio of 91.75 and a beta of 2.06. The company has a quick ratio of 8.32, a current ratio of 9.10 and a debt-to-equity ratio of 1.92. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The company's fifty day simple moving average is $125.04 and its 200 day simple moving average is $90.13.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.29 by $0.41. The company had revenue of $143.54 million during the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The firm's revenue for the quarter was up 48.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.35 earnings per share. On average, analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on TMDX shares. Piper Sandler restated an "overweight" rating and issued a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 17th. Finally, Oppenheimer increased their price objective on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a report on Tuesday, June 17th. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, TransMedics Group currently has an average rating of "Moderate Buy" and a consensus price target of $127.33.

Insider Activity

In related news, Director David Weill sold 732 shares of the stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total transaction of $90,680.16. Following the transaction, the director owned 12,134 shares of the company's stock, valued at approximately $1,503,159.92. This trade represents a 5.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward M. Basile sold 5,000 shares of the firm's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total transaction of $632,250.00. Following the completion of the sale, the director directly owned 2,866 shares in the company, valued at approximately $362,405.70. This trade represents a 63.56% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 12,418 shares of company stock worth $1,512,613. 7.00% of the stock is currently owned by corporate insiders.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.